These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 12566907

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Matsui K, Negoro S, Takifuji N, Nakagawa K, Hirashima T.
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
    de Jonge MJ, Verweij J, de Bruijn P, Brouwer E, Mathijssen RH, van Alphen RJ, de Boer-Dennert MM, Vernillet L, Jacques C, Sparreboom A.
    J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
    [Abstract] [Full Text] [Related]

  • 4. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
    Ueoka H, Tabata M, Kiura K, Shibayama T, Gemba K, Segawa Y, Chikamori K, Yonei T, Hiraki S, Harada M.
    Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
    [Abstract] [Full Text] [Related]

  • 5. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
    Allegrini G, Di Paolo A, Cerri E, Cupini S, Amatori F, Masi G, Danesi R, Marcucci L, Bocci G, Del Tacca M, Falcone A.
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
    Falcone A, Di Paolo A, Masi G, Allegrini G, Danesi R, Lencioni M, Pfanner E, Comis S, Del Tacca M, Conte P.
    J Clin Oncol; 2001 Aug 01; 19(15):3456-62. PubMed ID: 11481350
    [Abstract] [Full Text] [Related]

  • 8. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
    Kobayashi K, Shinbara A, Kamimura M, Takeda Y, Kudo K, Kabe J, Hibino S, Hino M, Shibuya M, Kudoh S.
    Cancer Chemother Pharmacol; 1998 Aug 01; 42(1):53-8. PubMed ID: 9619758
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
    Masi G, Falcone A, Di Paolo A, Allegrini G, Danesi R, Barbara C, Cupini S, Del Tacca M.
    Clin Cancer Res; 2004 Mar 01; 10(5):1657-63. PubMed ID: 15014016
    [Abstract] [Full Text] [Related]

  • 14. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
    Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M.
    Ann Oncol; 1995 Feb 01; 6(2):133-40. PubMed ID: 7786821
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
    Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Takifuji N, Nakagawa K, Tamanoi M, Nitta T, Hirashima T.
    Br J Cancer; 1993 Oct 01; 68(4):777-82. PubMed ID: 8398707
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T.
    J Clin Oncol; 1994 Sep 01; 12(9):1833-41. PubMed ID: 7521905
    [Abstract] [Full Text] [Related]

  • 17. [A case of advanced gastric cancer treated with neoadjuvant chemotherapy of low-dose CPT-11 + CDDP].
    Tadatomo H, Suzuki K, Ando M, Yamashita S, Tanaka K, Maruyama S, Harada Y, Ohnuma S, Sakaniwa N, Koyanagi Y.
    Gan To Kagaku Ryoho; 2001 Jun 01; 28(6):821-4. PubMed ID: 11432351
    [Abstract] [Full Text] [Related]

  • 18. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
    Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T.
    Eur J Cancer; 2015 May 01; 51(7):808-16. PubMed ID: 25797356
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.